Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRICOM vaccine
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Recombinant Proteins and Enzymes, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intralesional, Intratumoral, Intravesical, Subcutaneous
01
Overview
The TRICOM vaccine is a therapeutic cancer vaccine platform based on recombinant poxvirus vectors engineered to express a triad of human T-cell costimulatory molecules—B7-1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58)—alongside tumor-associated antigens. The inclusion of these three costimulatory molecules synergistically enhances antigen-specific T-cell responses against tumor antigens. Several specific vaccines have been developed using the TRICOM platform: - PROSTVAC (PSA-TRICOM): targets prostate-specific antigen for prostate cancer. - PANVAC (CEA-MUC1-TRICOM): targets carcinoembryonic antigen and MUC1 for various carcinomas. - MVA-BN-brachyury-TRICOM: targets brachyury in advanced cancers. These vaccines are designed to stimulate robust anti-tumor immune responses by improving the activation and proliferation of cytotoxic T-cells against cancer cells expressing the target antigens. The platform has shown safety and immunogenicity in multiple phase I/II clinical trials across several solid tumors[2][3][5][9].
- Other names
- PROSTVAC (for PSA-TRICOM)PANVAC (for CEA-MUC1-TRICOM)MVA-BN-brachyury-TRICOM vaccinevaccinia-TRICOM vaccine
02
Targets
CD28 (Cluster of Differentiation 28)LFA-1 (Integrin αLβ2)CD2 (T-cell Surface Antigen CD2)
Beyond the preview
Go deeper on TRICOM vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRICOM vaccine.